Breast cancer most frequently metastasizes to bone causing decreased quality of life and morbidity. Since current treatments are palliative, strategies to prevent bone metastases in breast cancer patients are required. There is substantial evidence indicating that high levels of nitric oxide (NO) suppress tumor growth and metastasis in vivo. We hypothesize that agents that produce high concentrations of NO could prevent the spread of breast cancer to bone. We previously demonstrated that the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) produces high levels of NO via the induction of NO synthases. NO prodrugs are designed to produce large amounts of NO without inducing NO synthases but upon metabolism by their intracellular targets. The objective of this study was to determine the effectiveness of 4-HPR and an NO prodrug, diethylamineNONOate/AM (NONO-AM), in inhibiting the growth and invasiveness of bone metastatic breast cancer cells. Parental MDA-MB-231 breast cancer cells were resistant to 4-HPR-induced apoptosis at clinically relevant doses, whereas 4-HPR-induced apoptosis in a dose-dependent manner in MDA-MB-231/F10 bone metastatic breast cancer cells. Unlike 4-HPR, NONO-AM induced apoptosis in a dose-dependent manner in both parental MDA-MB-231 cells and F10 cells. The bone metastatic F10 cells were more sensitive to the anti-invasive effects of 4-HPR and NONO-AM than were MDA-MB-231 cells. Although suppression of matrix metalloprotease-9 activity may be one mechanism by which 4-HPR decreases the invasion of F10 cells, it does not appear to be the antiinvasion mechanism of NONO-AM. These in vitro results suggest that 4-HPR and NO pro-drugs may be effective chemopreventive agents against bone metastatic breast cancer.
Introduction
As many as 85% of patients with advanced breast cancer develop bone metastases resulting in complications such as severe bone pain, fractures, hypercalcemia and spinal cord or nerve compression (1) . The morbidity from bone metastases in patients with breast cancer remains a significant health problem, accounting for 470% of breast cancer deaths (2, 3) . Despite the prevalence of this problem, there are currently no satisfactory therapies available and most are administered with palliative intent. Chemotherapy and hormonal therapy are the preferred systemic treatments for bone metastatic breast cancer, but they are typically associated with only temporary control of symptomatic disease. Surgery, radiation, bisphosphonates and analgesics are also used to reduce bone pain and to prevent or repair fractures. Therefore, there is a need for the development of chemopreventive agents that specifically prevent the spread of breast cancer to bone.
The free radical nitric oxide (NO) plays an important role in regulating tumor growth and metastasis; however, it remains controversial whether NO positively or negatively impacts these processes. The cellular origin and the concentration of NO in the tumor microenvironment are crucial in determining whether NO exhibits tumor promoting or tumor suppressing effects. NO is synthesized by three nitric oxide synthase (NOS) isoforms. NOSI and NOSIII are expressed constitutively and produce trace amounts of NO (low pM for seconds to minutes). In contrast, NOSII is the inducible isoform and can generate large amounts of NO (mM for hours to days). Patient samples and animal models indicate that NOSII expression in tumor cells reduces, while NOSII expression in host cells enhances, breast cancer metastasis (4) (5) (6) (7) . Low concentrations of NO may protect some cell types from apoptosis induced by DNAdamaging agents (8) and may increase the invasiveness and metastatic potential of murine tumors (9, 10) . In contrast, high concentrations of NO are cytotoxic (11) (12) (13) (14) (15) (16) and prevent murine tumor metastasis (17) . Recently, there have been a number of studies demonstrating that NOSII-mediated NO suppresses tumorigenesis and metastasis in vivo (4, 18, 19) . Therefore, molecules that can induce NOSII-mediated NO production in tumor cells could potentially be used as chemopreventive agents against bone metastatic breast cancer. One such molecule is the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR). We previously reported that 4-HPR at clinically relevant doses induces apoptosis in breast cancer cells by inducing NOSII-mediated NO production (15) . 4-HPR has also been shown to inhibit the invasion of several cancer cell types, including ovarian cancer (20) , prostate cancer (21-24) and Kaposi's sarcoma (25) .
Unlike 4-HPR, NO donors are designed to spontaneously generate large amounts of NO in aqueous media at physiological pH and temperature. However, this indiscriminate release of NO can have deleterious effects on the cardiovascular system and induce severe hypotension. To maximize NO exposure to tumor cells while minimizing undesirable side effects elsewhere in the body, NO pro-drugs have been designed to generate large amounts of NO upon metabolism by intracellular enzymes. The NO pro-drug diethylamine NONOate/AM (NONO-AM), which releases NO upon activation by intracellular esterases, has been shown to induce apoptosis in leukemia cells (26) .
Given their ability to produce large amounts of NO, 4-HPR and NONO-AM may hold promise for the prevention of bone metastases from breast cancer. The objective of this study was to determine the effects of 4-HPR and NONO-AM on the in vitro growth and invasiveness of bone metastatic breast cancer cells.
Materials and methods
Reagents 4-HPR was purchased from Sigma Chemical (St Louis, MO). NONO-AM, GM6001, GM6001-negative and matrix metalloprotease (MMP)-2/ MMP-9 inhibitor II {(2R)-[(4-biphenylsulfonyl)amino]-N-hydroxy-3-phenylpropionamide} were purchased from EMD Biosciences (La Jolla, CA). Matrigel was purchased from BD Biosciences (Bedford, MA). Hema-3 was purchased from Fisher Scientific (Middleton, VA). Casein and gelatin zymogram gels, non-reducing sample buffer, 10Â zymogram renaturing buffer, 10Â zymogram development buffer, Coomassie blue-R250 and Coomassie blue destaining solution were purchased from Bio-Rad Laboratories (Hercules, CA). Stock solutions of 4-HPR (10 mM), NONO-AM (10 mM), GM6001 (1 mM), GM6001-negative (1 mM) and MMP-2/MMP-9 inhibitor II (1 mM) were prepared in dimethyl sulfoxide and stored at À20
C. All reagents were diluted in the culture medium to the indicated final concentration.
Cell lines and culture conditions
The human MDA-MB-231 cell line was obtained from American Type Cell Culture (Manassas, VA). The MDA-MB-231 cell line is an estrogen independent highly metastatic human breast cancer cell line (27) . MDA-MB-231 cells metastasize predominantly to bone, but may spread to the brain, ovary and adrenal glands after inoculation into the left ventricle of the heart in female nude mice (28) . Since there are no commercially available bone metastatic breast cancer cell lines, we used a selective bone metastatic derivative of MDA-MB-231 cells, MDA-MB-231/F10. The MDA-MB-231/F10 cell line was established by inoculating MDA-MB-231 cells into the left ventricle of the heart of 6-week-old female nude mice. The tumor cells that metastasized to bone were isolated, grown in tissue culture and then reinoculated into the left ventricle of female nude mice. The cells that again metastasized to bone were isolated, expanded and reinoculated into the left ventricle of the heart. This process was repeated until no micrometastases were detected histologically or by X-ray in tissues other than bone within 4-5 weeks of injection. The MDA-MB-231/F10 cell line was established and kindly provided by Dr Yoneda (The University of Texas Health Science Center, San Antonio, Texas). F10 cells exclusively metastasize to bone after intracardiac inoculation in female nude mice (28) . MDA-MB-231 and F10 breast cancer cells were cultured in Dulbecco's modified Eagles medium (DMEM/F12) supplemented with 5% heat-inactivated fetal bovine serum (FBS) at 37 C under 5% CO 2 in a humidified incubator. Cell growth and NO assay MDA-MB-231 and F10 breast cancer cells were plated at 2.5 Â 10 4 cells/well in 6-well plates in 2 ml of DMEM/F12 supplemented with 5% FBS. After 24 h, cells were treated with 4-HPR (1, 2.5 mM) or NONO-AM (0-100 mM). After 5 days of incubation, cell growth was determined by total live cell counts using trypan blue exclusion. Supernatants were collected from untreated and treated cells and stored at À80 C until NO determination. Total NO was determined by quantifying nitrite, the stable end product of NO oxidation, spectrophotometrically using a Colorimetric non-enzymatic Nitric Oxide Assay Kit (Oxford Biomedical Research, Oxford, MI) as described previously (15) . Nitrite values were normalized for total cell counts and expressed as mM per one million cells. The values were reported as the mean (AE SD) of experiments performed in triplicate. Apoptosis assays MDA-MB-231 and F10 cells were plated at 2.5 Â 10 4 cells/well in 6-well plates in 2 ml of DMEM/F12 supplemented with 5% FBS. After 24 h, cells were treated with 4-HPR (1, 2.5 mM) or NONO-AM (40 mM). After 4 days of incubation, apoptosis was determined by using flow cytometry and immunohistochemistry. Cells were harvested and prepared for flow cytometry as described previously (15) . For immunohistochemistry, cells were collected and suspended at 1 Â 10 6 cells/ml in phosphate-buffered saline (PBS). Cytospins for each treatment were prepared using 100 ml of the appropriate cell suspension. Slides were quick-fixed in À20 C acetone and stored at À20 C until immunostaining. The FragEL TM DNA Fragmentation Detection Kit (EMD Biosciences, La Jolla, CA) was used to detect apoptotic nuclei according to the manufacturer's instructions. This kit allows the recognition of DNA breaks in apoptotic nuclei. In this assay, terminal deoxynucleotidyl transferase binds to exposed 3 0 OH ends of DNA fragments and catalyzes the addition of biotin-labeled and unlabeled deoxynucleotides. Biotinylated nucleotides are detected using a streptavidin-horseradish peroxidase conjugate. Diaminobenzidine reacts with the labeled sample to generate an insoluble brown substrate at the site of DNA fragmentation. Samples were counterstained with methyl green to aid in distinguishing between normal and apoptotic cells.
Matrigel invasion assay
The effect of 4-HPR and NONO-AM on the invasiveness of breast cancer cells was determined in vitro by determining the number of MDA-MB-231 and F10 cells that invaded through transwell inserts coated with the artificial basement membrane Matrigel. This assay was also used to determine the importance of MMP activity on the invasiveness of MDA-MB-231 and F10 cells. Briefly, 6-well plate transwell inserts with 8 mm pore-size polycarbonate filters (Fisher Scientific, Middleton, VA) were coated with Matrigel in cold serum-free DMEM/F12 at a final concentration of 0.7 mg/ml and placed at room temperature for 40 min. MDA-MB-231 and F10 cells were trypsinized, resuspended in serum-supplemented medium and counted. Cells were then washed three times with serum-free medium. Cells (3 Â 10 5 in 500 ml) were added into each transwell insert and incubated for 72 h in the absence and presence of 4-HPR (1, 2.5 mM) or NONO-AM (20, 40 mM). Cells were also incubated in the presence of the broad-spectrum MMP inhibitor GM6001 (10 mM) or an identical amount of its specific product of negative control, GM6001-negative, or a specific MMP-2/MMP-9 inhibitor (10 mM) for 72 h. The lower chambers were filled with 2 ml of DMEM/F12 medium supplemented with 5% FBS. After incubation, non-invading cells on the upper surface of the filter were removed with cotton swabs. Cells that had passed through the pores onto the lower side of the filter were fixed, stained with Hema-3 and photographed. The migrated cells were counted in five fields for each filter under a light microscope at 40Â magnification. The invasive ability of the cells was expressed as the mean number of cells that had invaded to the lower side of the filter. The experiments were performed in triplicate and repeated twice. Zymographic analysis of MMP activity MDA-MB-231 and F10 cells (3 Â 10 5 ) were plated in T-25 flasks and incubated for 24 h in the absence or presence of 4-HPR (1, 2.5 mM) or NONO-AM (20, 40 mM). MDA-MB-231 and F10 cells were also incubated for 24 h with the MMP-2/MMP-9 inhibitor (10 mM) to verify the downregulation of MMP-9 activity. Cells were changed to serum-free medium the next day for 24 h. The medium was recovered and centrifuged for 5 min. The conditioned medium was collected and concentrated by using spin columns with 10-kDa-cutoff filters (Millipore, Bedford, MA). Concentrated conditioned medium (20 ml) was mixed (1:1) with non-reducing sample buffer, incubated at 37 C for 15 min, and then applied to gelatin and casein zymogram gels. After electrophoresis, the gels were incubated for 3 h in zymogram renaturing buffer at room temperature with gentle agitation, followed by an overnight incubation in zymogram development buffer at 37 C. The gels were stained with Coomassie blue-R250 for 3 h and then destained with Coomassie blue destaining solution. Gelatinase and caseinase activities were visible as clear bands against the dark blue background, indicating proteolysis of the substrate protein.
Statistical analyses
For statistical analysis of the invasion experiments, the Shapiro-Wilk test was first performed to assess the normality assumption of the data. Given that the data was normally distributed, two-sample t-tests were performed for each cell line to compare the number of invading cells for the untreated group with the number of invading cells for each of the 4-HPR doses. In addition, the number of invading cells was compared between the two 4-HPR doses. These analyses were also performed for the NONO-AM, GM6001 and MMP-2/MMP-9 inhibitor treatments used in the invasion experiments. The significance level for each individual comparison was adjusted by the Bonferroni method to account for multiple testing within each cell line to achieve an overall significance level of 0.05. All analyses were performed using SASÒ.
Results

4-HPR's induction of apoptosis in F10 bone metastatic breast cancer cells was correlated with NO production
To assess the effect of 4-HPR on the growth of breast cancer cells, MDA-MB-231 and F10 cells were treated with 4-HPR. The two experimental doses 1 and 2.5 mM were chosen because they are clinically achievable (29) . MDA-MB-231
Effects of 4-HPR and NONO-AM on bone metastatic breast cancer cells cells were resistant to 4-HPR-induced growth inhibition (Table I) . In contrast, 4-HPR at 1 and 2.5 mM inhibited the growth of F10 cells by 53 and 69%, respectively. NO production increased 3.4-and 5.5-fold in F10 cells treated with 1 and 2.5 mM 4-HPR, respectively (Table I) . In contrast, NO production was not induced in MDA-MB-231 cells treated with 4-HPR. Thus, the growth inhibitory effects of 4-HPR were directly correlated with increases in NO production in F10 cells.
Flow cytometric analysis of propidium iodide-stained cells was used to determine whether apoptosis was related to the growth inhibition found in 4-HPR-treated bone metastatic breast cancer cells ( Figure 1A ). 4-HPR increased the percentage of apoptotic F10 cells in a dose-dependent manner ( Figure 1A) . The number of apoptotic F10 cells was increased from 1.1 to 26.7 and 47.3% by the 1 and 2.5 mM doses of 4-HPR, respectively ( Figure 1A) . The apoptotic effects of 4-HPR were confirmed by using DNA fragmentation ( Figure 1B ). These data indicate that F10 bone metastatic breast cancer cells were sensitive to pharmacologically achievable doses of 4-HPR.
NONO-AM induced apoptosis in MDA-MB-231 and F10 breast cancer cells To assess the effect of NONO-AM on the growth of breast cancer cells, MDA-MB-231 and F10 cells were treated with increasing concentrations of NONO-AM (0-100 mM). In contrast to 4-HPR, NONO-AM inhibited the growth of both MDA-MB-231 and F10 cells in a dose-dependent manner (Figure 2A) . The IC 50 of NONO-AM was between 20 and 40 mM in both cell lines. Growth inhibition in NONO-AMtreated cells was correlated with dose-dependent increases in NO concentration ( Figure 2B ). To determine whether apoptosis was related to the growth inhibition found in the breast cancer cell lines treated with NONO-AM, MDA-MB-231 and F10 cells were treated with NONO-AM (40 mM) and examined by flow cytometry ( Figure 2C ). NONO-AM increased the number of apoptotic cells from 2.2 to 35% for MDA-MB-231 cells and from 1.7 to 46.8% for F10 cells ( Figure 2C ). The apoptotic effects of NONO-AM were confirmed by using DNA fragmentation ( Figure 2D ). These data indicate that both the parental and the F10 bone metastatic breast cancer cells were sensitive to the apoptotic effects of NONO-AM. 
F10 bone metastatic breast cancer cells were more sensitive to the anti-invasive effects of 4-HPR and NONO-AM
We examined the effect of 4-HPR and NONO-AM on the invasive ability of MDA-MB-231 and F10 cells by using the Matrigel invasion assay. To avoid confounding any antiinvasive effects of 4-HPR and NONO-AM with their proapoptotic effects, these experiments were performed under conditions (initial plating density and treatment duration) in which 510% growth inhibition was induced (data not shown). Untreated MDA-MB-231 and F10 cells displayed a high invasive capacity on Matrigel ( Figure 3A ). 4-HPR significantly (P 5 0.05) reduced the number of invasive cells in both cell lines; however, F10 cells were more sensitive to the antiinvasive effects of 4-HPR ( Figure 3A ). Significant inhibition (P 50.05) of invasion was observed in F10 cells (74%) and a smaller but significant (P 5 0.05) decrease in invasion (28%) was observed in MDA-MB-231 cells after treatment with 1 mM 4-HPR ( Figure 3B ). The 2.5 mM dose of 4-HPR had a similar anti-invasive effect in MDA-MB-231 (74%) and F10 cells (77%; Figure 3B ). The two doses of 4-HPR did not have significantly different anti-invasive effects in F10 cells.
In contrast to 4-HPR, NONO-AM inhibited the invasion of F10 cells but not MDA-MB-231 cells ( Figure 4A ). At 20 and 40 mM, NONO-AM significantly (P 5 0.05) reduced the number of invading F10 cells by 60 and 75%, respectively, compared with untreated cells ( Figure 4B ). The two doses of NONO-AM did not have significantly different anti-invasive effects in F10 cells ( Figure 4B ).
Effects of 4-HPR and NONO-AM on MMP activities
MMPs, which are essential to the invasive process, are involved in the degradation of the extracellular matrix and basement membranes. To confirm that MMP activity was important for the invasiveness of MDA-MB-231 and F10 cells, the broad-spectrum MMP inhibitor GM6001 (10 mM) was used to block MMP activity in a Matrigel invasion assay. GM6001 at the dose used was not cytotoxic to either cell line (data not shown). Inhibition of MMP activity significantly Effects of 4-HPR and NONO-AM on bone metastatic breast cancer cells (P 5 0.05) decreased the invasiveness of MDA-MB-231 and F10 cells ( Figure 5A ). The number of invaded cells was decreased 40 and 54% in MDA-MB-231 and F10 cells, respectively, by treatment with GM6001 ( Figure 5B ). In contrast, GM6001-negative, the specific product of negative control for GM6001, did not influence the invasive ability of either cell line ( Figure 5A and B) .
To determine whether 4-HPR and NONO-AM decreased the invasive potential of breast cancer cells by blocking MMP activities, casein and gelatin zymography was performed on untreated and treated MDA-MB-231 and F10 cells. MMP-9 and MMP-2 activities were detected by gelatin zymography in the supernatants of untreated MDA-MB-231 and F10 cells ( Figure 5C ). The activity of MMP-9 was greater than that of MMP-2 in both cell lines and was greater in F10 cells than in MDA-MB-231 cells. MMP-9 activity decreased in a dose-dependent manner in MDA-MB-231 cells treated with 4-HPR, whereas only the 2.5 mM dose of 4-HPR decreased MMP-9 activity in F10 cells. NONO-AM had no effect on MMP-9 activity in either cell line. MMP-2 activity was not affected by treatment with 4-HPR or NONO-AM in either cell line. Casein zymography revealed two protease bands with molecular weights of $40-56 kDa in untreated F10 cells ( Figure 5D ). These bands may correspond to the stromelysins MMP-3 and MMP-10 or may represent an MMP-3 doublet (30) . Caseinase activities were not altered in MDA-MB-231 and F10 cells by treatment with 4-HPR or NONO-AM. Since 4-HPR decreased MMP-9 activity in MDA-MB-231 and F10 cells, the importance of MMP-9 in the invasiveness of these cell lines was determined. A specific MMP-9 inhibitor (10 mM) was used to block MMP-9 activity of the cell lines in a Matrigel invasion assay. The MMP-9 inhibitor at the dose used was not cytotoxic to either cell line (data not shown). The inhibitor suppressed MMP-9 activity as revealed by gelatin zymography (data not shown). Inhibition of MMP-9 activity significantly (P 5 0.05) decreased the invasiveness of MDA-MB-231 and F10 cells ( Figure 5E ). The number of invaded cells was decreased 39 and 41% in MDA-MB-231 and F10 cells, respectively, by treatment with the MMP-9 inhibitor ( Figure 5F ). Therefore, suppression of MMP-9 activity may be one mechanism by which 4-HPR decreased the invasive behavior of the breast cancer cell lines.
Discussion
We found that the F10 bone metastatic breast cancer cells were sensitive to the apoptotic and anti-invasive effects of 4-HPR and NONO-AM. Both drugs produce high levels of NO but by different mechanisms. 4-HPR induces NO production by increasing NOSII expression in breast cancer cells (15), whereas NONO-AM releases NO when activated by intracellular esterases (26) . We found that 4-HPR selectively induced apoptosis in F10 cells but not in MDA-MB-231 cells. On the other hand, NONO-AM was effective in inducing apoptosis in both cell lines. These data indicate that both the parental and the bone metastatic cells are sensitive to NO-mediated apoptosis. However, the parental cells may possess intrinsic resistance mechanisms that could prevent 4-HPR from inducing NO, probably by preventing 4-HPR from inducing NOSII expression, as is the case in HER2/neu-overexpressing breast cancer cells (31) . The invasiveness of F10 cells was suppressed by 4-HPR and NONO-AM, suggesting that the bone metastatic breast cancer cells are highly sensitive to NO-mediated anti-invasive effects. In contrast, the invasiveness of the parental MDA-MB-231 cells appears to be insensitive to NO, since NONO-AM, Effects of 4-HPR and NONO-AM on bone metastatic breast cancer cells which could generate large amounts of NO in MDA-MB-231 cells, did not decrease the invasive activity of these cells. Surprisingly, 4-HPR decreased the invasive activity of both MDA-MB-231 and F10 cells, albeit more effectively in F10 cells. In unpublished observations, cDNA microarray analysis of 4-HPR-modulated genes in MDA-MB-231 and F10 cells did not reveal any gene expression changes 42-fold on Affymetrix U133A and U133B GeneChips. In MDA-MB-231 cells, 4-HPR-modulated the expression of 19 genes by 1.5-fold on the Affymetrix U133A GeneChip and 15 genes on the Affymetrix U133B GeneChip. Some of these genes included thrombospondin-1, interleukin-8 and the C-X-C motif ligands 1, 2 and 3. In F10 cells, 4-HPR did not induce any gene expression changes 41.5-fold in either GeneChip. These data suggest that the induction of apoptotic and anti-invasive effects by 4-HPR in breast cancer cells does not occur at the transcriptional level.
MDA-MB-231 cells have been shown to secrete the gelatinase MMP-9 and the caseinase MMP-3 (32-34). In the present study, suppression of MMP-9 activity, but not MMP-2 or caseinase activities (MMP-3/MMP-10), was observed in MDA-MB-231 and F10 cells treated with 4-HPR. MMP-9 activity was important in the invasiveness of MDA-MB-231 and F10 cells since suppression of MMP-9 activity decreased the number of invaded cells. In MDA-MB-231 cells, 4-HPR decreased MMP-9 activity in a dose-dependent manner, which corresponded with the dose-dependent decrease in invasion. In F10 cells, invasion was inhibited to a similar degree by treatment with either 1 or 2.5 mM 4-HPR; however, decreased MMP-9 activity was observed only at the 2.5 mM dose. Suppressing the activity of MMP-9 may be one mechanism by which 4-HPR decreases the invasive behavior of MDA-MB-231 and F10 cells. However, it is apparent from these results that 4-HPR uses more than one mechanism to suppress the invasiveness of metastatic breast cancer cells. MDA-MB-231 cells have been shown to secrete the interstitial collagenases MMP-1 and MMP-13 (32) . It is possible that 4-HPR may decrease the activity of these MMPs to suppress invasion. In addition, 4-HPR inhibited the invasion of transformed BALB/c 3T3 cells and prostate cancer cells by suppressing chemotactic motility (35) and by altering cellular adhesion to the extracellular matrix (21, 35) , so the drug may also use these mechanisms to inhibit the invasive capacity of metastatic breast cancer cells. Interestingly, NONO-AM did not have any effect on gelatinase or caseinase activities in F10 cells, indicating that the drug may have affected invasion by altering the activity of MMPs that we did not evaluate or by altering cellular adhesion.
Bone is the most frequent site of metastatic disease in patients with advanced breast cancer, and the prognosis in these patients is generally poor. According to National Cancer Institute, only 10-20% of women with metastatic breast cancer survive the disease and achieve permanent remission. Current treatments, including chemotherapy, hormonal therapy and radiotherapy, are generally administered with palliative intent; therefore, chemoprevention to prevent the formation of bone metastases could have a profound effect on the incidence of bone metastases and associated mortality rate. Bisphosphonates are an effective palliative treatment for bone metastatic breast cancer, but randomized clinical trials investigating the adjuvant use of bisphosphonates to prevent bone metastases have yielded conflicting results. Diel et al. (36) and Powles et al. (37) reported a reduction in the occurrence of bone metastases from breast cancer and an increase in overall survival in patients with primary breast cancer who received adjuvant clodronate for 2 years. However, a decrease (38) or lack of effect (37) of clodronate was evident at the 5-year follow-up. In contrast, Saarto et al. (39) found that 3 years of adjuvant clodronate had no effect on the occurrence of bone metastases and a negative effect on the occurrence of non-bone metastases as well as survival in breast cancer patients. Therefore, chemopreventive strategies that specifically prevent the occurrence of bone metastases from breast cancer are urgently needed. The results of the present in vitro studies indicate the potential of 4-HPR and NO pro-drugs as chemopreventive agents against bone metastases from breast cancer and warrant their further evaluation in in vivo chemoprevention studies.
